Summary
The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric Research Equity Act (PREA). RACE Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This paper discusses the need for and the importance of pediatric research, the RACE Act, and how it applies to precision medicine.
Register to download
RACE Act Prompts More Pediatric Clinical Trials for Oncology Drug Developers
You may also be interested in:
Blog
Ensuring Children’s Voices are Heard in Clinical Trials
World Children’s Day at PRA Health Sciences recognizes children’s rights to safe and effective treatments. This year, the teams from PRA’s Center for…
Blog
How to Improve Access to New Medicine for Adolescents
Blog
Perspectives and Stories from the Pediatric Collaboration Team
The Center for Pediatric Clinical Development (CPCD) is comprised of 11 dedicated staff members who share diverse healthcare and research…